Antibiotic dosing in children in Europe: Can we grade the evidence from pharmacokinetic/pharmacodynamic studies - And when is enough data enough?

Current Opinion in Infectious Diseases

Volumn 25, Issue 3, 2012, Pages 235-242

  Barker, Charlotte I S ^a,b   Standing, Joseph F ^c   Turner, Mark A ^d   McElnay, James C ^e   Sharland, Mike ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

antimicrobials; children; pharmacodynamics; pharmacokinetics

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; FLUCLOXACILLIN; PENICILLIN V;

ANTIBIOTIC RESISTANCE; DOSE RESPONSE; DRUG CLEARANCE; DRUG FORMULARY; EUROPE; HUMAN; NONLINEAR SYSTEM; OBESITY; OUTCOME ASSESSMENT; PATENT; PATIENT SAFETY; PEDIATRICIAN; PHARMACIST; PHARMACODYNAMICS; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SYSTEMATIC REVIEW (TOPIC);

ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPE; FORMULARIES AS TOPIC; HUMANS; MODELS, BIOLOGICAL; PEDIATRICS; PHARMACOLOGY, CLINICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84861099537     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328353105c     Document Type: Review

References (45)

1. Spyridis N, Sharland M. The European Union Antibiotic Awareness Day: The paediatric perspective. Arch Dis Child 2008; 93:909-910.
2. Harnden A, Perera R, Brueggemann AB, et al. Respiratory infections for which general practitioners consider prescribing an antibiotic: A prospective study. Arch Dis Child 2007; 92:594-597.
3. Sharland M. The use of antibacterials in children: A report of the Specialist Advisory Committee on Antimicrobial Resistance (SACAR) Paediatric Subgroup. J Antimicrob Chemother 2007; 60 (Suppl 1): I15-i26.
4. Ahmed U, Spyridis N, Wong IC, et al. Dosing of oral penicillins in children: Is big child = half an adult, small child=half a big child, baby = half a small child still the best we can do? BMJ 2011; 343:d7803. This British Medical Journal (BMJ) 'feature' provides an overview of the limited evidence behind the oral penicillin dosing regimes recommended in the BNFC. The study also explores the evidence for potential underdosing of antimicrobials in many children today that may result from the use of age brackets rather than weight brackets for dosing decisions, in an age of increasing childhood obesity.
5. Global Research in Paediatrics: Network of excellence (GRIP). http://gripnetwork. org/. [Accessed 31 January 2012]
6. Drusano GL. Antimicrobial pharmacodynamics: Critical interactions of 'bug and drug'. Nat Rev Microbiol 2004; 2:289-300.
7. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in Gram-negative pneumonia. Am J Med 1984; 77:657-662.
8. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials. JAMA 1998; 279:125-129.
9. Lutsar I, Metsvaht T. Understanding pharmacokinetics/pharmacodynamics in managing neonatal sepsis. Curr Opin Infect Dis 2010; 23:201-207.
10. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology- drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349:1157-1167.
11. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48:303-332.
12. Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 2006; 45:931-956.
13. van den Anker JN, Pokorna P, Kinzig-Schippers M, et al. Meropenem pharmacokinetics in the newborn. Antimicrob Agents Chemother 2009; 53:3871-3879.
14. De Cock RF, Piana C, Krekels EH, et al. The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol 2011; 67 (Suppl 1):5-16. This review explores the role of paediatric population PK/PD studies with reference to nonlinear mixed effect modelling, allowing analysis of sparse and unbalanced datasets. The review also discusses evaluation of the predictive performance of these models by different validation methods including prospective clinical trials and how to optimize the design of paediatric studies.
15. Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect 2001; 7:589-596.
16. Mouton JW, Ambrose PG, Canton R, et al. Conserving antibiotics for the future: New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist Updat 2011; 14:107-117. This study presents an excellent insight into the rational use of PK/PDdata to optimize antimicrobial dosing regimens, with specific focus on achieving the requisite microbiological and clinical outcomes while simultaneously suppressing emergence of resistance. The application of PK/PD to drug development is considered, as is the need to urgently establish the PK/PD profiles of older antibiotics.
17. Viberg A, Cars O, Karlsson MO, Jonsson S. Estimation of cefuroxime dosage using pharmacodynamic targets, MIC distributions, and minimization of a risk function. J Clin Pharmacol 2008; 48:1270-1281.
18. Ribbing J, Jonsson EN. Power, selection bias and predictive performance of the population pharmacokinetic covariate model. J Pharmacokinet Pharmacodyn 2004; 31:109-134.
19. Standing JF, Hammer GB, Sam WJ, Drover DR. Pharmacokinetic- pharmacodynamic modeling of the hypotensive effect of remifentanil in infants undergoing cranioplasty. Pediatr Anesth 2010; 20:7-18.
20. Kaguelidou F, Turner MA, Choonara I, Jacqz-Aigrain E. Ciprofloxacin use in neonates: A systematic review of the literature. Pediatr Infect Dis J 2011; 30:E29-E37. This study systematically reviewed observational cohort studies, case reports, and patient series regarding the use of ciprofloxacin in neonates; however, due to the heterogeneity of study designs and clinical contexts, no pooled analyses of outcomes were conducted. Although the findings provided someinformation to support the use of ciprofloxacin in neonates, additional high-quality studies are warranted to further investigate the pharmacokinetics, efficacy, and long-term safety.
21. Standing JF, Tibboel D, Korpela R, Olkkola KT. Diclofenac pharmacokinetic meta-analysis and dose recommendations for surgical pain in children aged 1-12 years. Pediatr Anesth 2011; 21:316-324. This pharmacokinetic meta-analysis comprised a pooled population analysis using nonlinear mixed effects modelling to define the pharmacokinetics of diclofenac in children administered by different routes, and to identify recommended routespecific dosing regimens. The meta-analysis shows the clinical relevance and potential patient benefit of using knowledge derived from well-designed pooled analyses of pharmacokinetic data.
22. Standing JF, Savage I, Pritchard D, Waddington M. Diclofenac for acute pain in children. Cochrane Database Syst Rev 2009:CD005538.
23. Potts AL, Anderson BJ, Warman GR, et al. Dexmedetomidine pharmacokinetics in pediatric intensive care: A pooled analysis. Paediatr Anaesth 2009; 19:1119-1129.
24. Anderson BJ, Merry AF. Data sharing for pharmacokinetic studies. Pediatr Anesth 2009; 19:1005-1010.
25. Phillips R, Ball C, Sackett D, et al. Oxford Centre for Evidence-based Medicine: Levels of evidence (March 2009). http://www.cebm.net/index.aspx? o=1025. [Accessed 31 January 2012]
26. Roy A, Ette EI. A pragmatic approach to the design of population pharmacokinetic studies. AAPS J 2005; 7:E408-E420.
27. European Committee on Antimicrobial Susceptibility Testing: EUCAST 2012. http://www.eucast.org/. [Accessed 31 January 2012]
28. Laer S, Barrett JS, Meibohm B. The In Silico Child: Using simulation to guide pediatric drug development and manage pediatric pharmacotherapy. J Clin Pharmacol 2009; 49:889-904.
29. BNF for Children. http://bnfc.org/bnfc/. [Accessed 31 January 2012]
30. Elias-Jones A, Rylance G. The launch of the British National Formulary for Children. Arch Dis Child 2005; 90:997-998.
31. Morrish GA, Pai MP, Green B. The effects of obesity on drug pharmacokinetics in humans. Expert Opin Drug Metab 2011; 7:697-706. This review discusses the physiological changes of obesity and their influence on body composition. Dosing metrics currently used to scale for size are considered, with examination of the nonlinear relationships between body composition and pharmacokinetic parameters.
32. Pickering LK, Baker CJ, Kimberlin DW, Long SS, editors. Red Book: 2009 Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics 2009. http://aapredbook.aappublications. org/. [Accessed 31 January 2012]
33. Drug Formulary for Children. Geneesmiddelencommissie: Geneesmiddelenformularium voor kinderen. Wilhelmina Kinderziekenhuis [in Dutch]. 2003 ed. Utrecht, Universitair Medisch Centrum; 2003.
34. Bradley JS, Nelson JD. Nelson's Pocket Book of Pediatric Antimicrobial therapy. 18th ed. Illinois, USA: American Academy of Pediatrics; 2010.
35. Bonati M, Pandolfini C. Is it time for a European formulary of paediatric medicines? Arch Dis Child 2004; 89:890-891.
36. World Health Organization. WHO model lists of essential medicines. http://whqlibdoc.who.int/hq/2011/a95054-eng.pdf. [Accessed 31 January 2012]
37. Medicines and Healthcare Products Regulatory Agency. Marketing authorisations. http://www.mhra.gov.uk/Howweregulate/Medicines/ Licensingofmedicines/Marketingauthorisations/index.htm. [Accessed 31 January 2012]
38. Medicines and Healthcare Products Regulatory Agency. Summary of regulation on medicines for paediatric use. http://www.mhra.gov.uk/home/groups/ pl-a/documents/websiteresources/con2025602.pdf. [Accessed 31 January 2012]
39. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH): Efficacy Guidelines. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/ E6-R1/Step4/E6-R1-Guideline.pdf. [Accessed 31 January 2012]
40. Smyth RL. A risk adapted approach to the governance of clinical trials. BMJ 2011; 343:d6756. In this BMJ editorial, researchers are encouraged to support the new risk-adapted approach to the regulation of clinical trials of investigational medicinal products: Trials using a product according to European Union-licensed indications (or offlabel use in a manner that is well established in clinical practice, e.g. in paediatric usage) need only be notified to the Medicines and Healthcare products Regulatory Agency (MHRA) and may proceed after 14 days from receipt of notification if the MHRA has not raised objections. This new initiative should be embraced, particularly in paediatric research, to facilitate proportionate regulation of clinical studies.
41. Medicines and Healthcare Products Regulatory Agency. Is a clinical trial authorisation required? http://www.mhra.gov.uk/Howweregulate/Medicines/ Licensingofmedicines/Clinicaltrials/Isaclinicaltrialauthorisationrequired/index. htm. [Accessed 31 January 2012]
42. Suyagh M, Collier PS, Millership JS, et al. Metronidazole population pharmacokinetics in preterm neonates using dried blood-spot sampling. Pediatrics 2011; 127:E367-E374. This prospective study investigated the pharmacokinetics of metronidazole in preterm neonates, using high-performance liquid chromatography on dried blood spots and nonlinear mixed effect modelling to define a new, more appropriate dosage regimen. The results demonstrated that the novel technique of dried blood spot-HPLC assay for the determination of metronidazole in neonatal whole blood samples could be used to develop and validate a new pharmacokinetic model.
43. European Medicines Agency EMA//98717/2012 Rev. 2012. Human Medicines Development and Evaluation. Revised priority list for studies into off-patent paediatric medicinal products for the 5th Call 2011 of the 7th Framework Programme of the European Commission. http://www.ema.europa.eu/docs/en-GB/ document-library/Other/2009/10/WC500004017.pdf. [Accessed 31 January 2012]
44. European Genetic Alliances' Network (EGAN): Patients Network for Medical Research and Health. Global Research in Paediatrics (GRIP). http://www. egan.eu/en/projects/grip. [Accessed 31 January 2012]
45. Antibiotic Resistance and Prescribing in European Children (ARPEC). http://www.arpecproject.eu/. [Accessed 31 January 2012]